Patients with human epidermal growth factor receptor 2 (HER2)–positive early breast cancer with residual invasive disease after neoadjuvant systemic therapy have a high risk of recurrence and death.

Stage IV, T3bN0M1 clear cell renal cell carcinoma, with an associated tumor thrombus extending into ... adjuvant immunotherapy with the minimally invasive approach. 41 However, limitations of ...

High-risk, non-muscle-invasive bladder cancer is defined as any transitional cell carcinoma (TCC) of the bladder that is high-grade, whether it is primary or recurrent. This high-risk group ...